Retatrutide vs Tirzepatide vs Semaglutide: Which Peptide Is Best?

The Quick Comparison

Here's the high-level breakdown of the three most effective weight loss peptides:

Head-to-Head Comparison: Detailed Breakdown

Weight Loss Results: Clinical Trial Data

Let's break down exactly how much weight people lost in clinical trials for each medication:

Retatrutide: 24-28.7% Weight Loss

Phase 2 Trial (48 weeks): Participants on 12mg weekly lost an average of 24.2% of their body weight.

Phase 3 Trial (TRIUMPH-1, 2025): The highest dose group lost an average of 28.7% of body weight—up to 71.2 pounds on average.

For a 240-pound person:

• 24% loss = 58 pounds
• 28.7% loss = 69 pounds

Tirzepatide: 15-22.5% Weight Loss

SURMOUNT-1 Trial (72 weeks): Participants on 15mg weekly (highest dose) lost an average of 22.5% of body weight.

For a 240-pound person:

• 15% loss (5mg dose) = 36 pounds
• 22.5% loss (15mg dose) = 54 pounds

Semaglutide: 10-15% Weight Loss

STEP 1 Trial (68 weeks): Participants on 2.4mg weekly lost an average of 14.9% of body weight.

For a 240-pound person:

• 10% loss (lower doses) = 24 pounds
• 15% loss (2.4mg dose) = 36 pounds

How Each Peptide Works: Mechanism Explained

Retatrutide: Triple Agonist (GLP-1 + GIP + Glucagon)

Retatrutide targets THREE hormone receptors:

• GLP-1: Reduces appetite, slows stomach emptying → you feel full longer
• GIP: Enhances insulin secretion, improves fat metabolism
• Glucagon: Increases energy expenditure, promotes fat burning

Why it's more effective: The glucagon receptor activation is the key differentiator. It boosts your metabolic rate and helps your body burn stored fat more aggressively.

Tirzepatide: Dual Agonist (GLP-1 + GIP)

Tirzepatide targets TWO hormone receptors:

• GLP-1: Appetite suppression and delayed gastric emptying
• GIP: Improved glucose control and fat metabolism

Why it's effective: The dual-agonist approach works better than GLP-1 alone. GIP activation enhances the weight loss effects and improves metabolic health markers.

Semaglutide: Single Agonist (GLP-1)

Semaglutide targets ONE hormone receptor:

• GLP-1: Reduces hunger signals, slows digestion, improves blood sugar control

Why it still works: GLP-1 is a powerful mechanism for weight loss. While it's "less advanced" than dual or triple agonists, it's proven, safe, and effective for many people.

Cost Comparison: What You'll Actually Pay

Brand-Name Pricing (Without Insurance)

• Retatrutide: $900-1,400/month (estimated—not available yet)
• Tirzepatide (Zepbound): $900-1,200/month
• Semaglutide (Wegovy): $900-1,400/month

Insurance Coverage: Most plans DON'T cover weight loss medications. Even if covered, expect high copays ($50-200/month).

Compounded Pricing (Most Affordable Option)

• Retatrutide: Unknown—depends on FDA compounding regulations when approved
• Tirzepatide: $179-499/month through telemedicine providers
• Semaglutide: $179-349/month through telemedicine providers

Why compounded is cheaper: Made by licensed US pharmacies using the same FDA-approved active ingredient, but without brand-name markup. No insurance needed.

Side Effects: What to Expect

All three medications share similar side effects because they activate GLP-1 receptors:

Common Side Effects (All Three)

• Nausea (most common, usually temporary)
• Diarrhea or constipation
• Vomiting
• Reduced appetite (therapeutic effect)
• Abdominal discomfort

Which Has the Worst Side Effects?

Surprisingly similar across all three. Clinical trial data shows:

• Tirzepatide: Slightly more GI side effects than semaglutide (due to dual agonist effect)
• Retatrutide: Similar to tirzepatide—adding glucagon didn't significantly worsen side effects
• Semaglutide: Slightly fewer GI issues, but differences are modest

Which Should You Choose? Decision Framework

The Practical Answer: Start Tirzepatide Now, Consider Retatrutide Later

Here's what most people should do:

1. Start tirzepatide NOW if you need to lose weight and don't want to wait 1-2 years
2. Lose significant weight with tirzepatide (15-22.5% is excellent!)
3. Switch to retatrutide when available if you've plateaued or want even better results

Why this makes sense:

• Waiting until 2027-2028 means another 1-2 years of carrying excess weight
• Tirzepatide delivers excellent results—you'll see dramatic improvements
• You can always switch medications later (doctors do this all the time)
• Starting now means you're 50+ pounds lighter when retatrutide launches!

Where to Get Tirzepatide and Semaglutide Now

The fastest, most affordable way to get started is through telemedicine providers offering compounded versions:

Can You Switch Between These Medications?

Yes! Switching between GLP-1 medications is common and safe. Here's how it typically works:

Switching From Semaglutide → Tirzepatide

• Common when people plateau on semaglutide
• Your provider will start you on a low tirzepatide dose and titrate up
• Usually a seamless transition with minimal side effects

Switching From Tirzepatide → Retatrutide (When Available)

• Expect similar transition protocols as semaglutide to tirzepatide
• Start low on retatrutide, gradually increase
• Your doctor will monitor closely during the first few weeks

Switching From Tirzepatide → Semaglutide

• Less common (why downgrade?), but possible if cost is a concern
• Some people respond better to semaglutide's single-agonist approach

The Bottom Line: Which Peptide Wins?

Best Overall (Effectiveness): Retatrutide — but it's not available until 2027-2028

Best Right Now: Tirzepatide — delivers excellent results (15-22.5% weight loss) and you can start today

Best Value: Tie between tirzepatide and semaglutide at $179-349/month compounded

Best for Most People: Start tirzepatide now, then consider switching to retatrutide when it's FDA-approved if you want even better results or have plateaued.

Related Reading:

• What Is Retatrutide? Complete Guide to the Next-Gen Peptide
• Retatrutide Cost: How Much Will It Cost When Available?
• How to Get Tirzepatide Without Insurance (2026)
• Semaglutide vs Tirzepatide: Which Is Better?